Clinical Trials Browser

Completed × Neoplasms × lenvatinib × Clear all

Neoplasms

NCT02720068 2025-05-30

MK-4280-001

Phase 1 Completed

481 enrolled 36 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

Phase 2 Completed

29 enrolled 13 charts

Tumor-Agnostic

Neoplasms

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Tumor-Agnostic

Neoplasms

NCT02432274 2023-07-11

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Phase 1/2 Completed

117 enrolled 32 charts

Sarcoma

Neoplasms, Osteosarcoma

NCT00121719 2023-06-22

An Open Label Dose Escalation Study Of E7080

Phase 1 Completed

82 enrolled 34 charts

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Neoplasms

NCT01268293 2023-06-22

A Study of E7080 in Subjects With Solid Tumor

Phase 1 Completed

9 enrolled 6 charts

Tumor-Agnostic

Neoplasms

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT04008082 2022-03-08

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Completed

412 enrolled

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms, Neoplasms, Glandular and Epithelial

NCT02686164 2019-08-28

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Phase 1 Completed

51 enrolled 11 charts

Tumor-Agnostic

Neoplasms

NCT00280397 2016-10-07

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Phase 1 Completed

27 enrolled 8 charts

Tumor-Agnostic

Neoplasms

NCT00121680 2015-12-11

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

Phase 1 Completed

115 enrolled

Dermatologic

Melanoma, Neoplasms

NCT00832819 2015-04-30

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

28 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT01240408 2015-03-04

E7080 Food Effect Study in Healthy Subjects

Phase 1 Completed

16 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

MK-4830-001

MK-4280-001

Eribulin and Lenvatinib in Advanced Solid Tumors

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

An Open Label Dose Escalation Study Of E7080

A Study of E7080 in Subjects With Solid Tumor

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma

E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)

E7080 Food Effect Study in Healthy Subjects